期刊文献+

荜茇明碱类似物合成与抗宫颈癌HeLa细胞活性研究 被引量:1

The Synthesis and Anti-cervical Cancer HeLa Cell Proliferation Activity of Piperlongumine and Its Analogues
下载PDF
导出
摘要 本文设计合成了8个荜茇明碱类似物,评价了它们体外抗宫颈癌HeLa细胞增殖活性.发现将荜茇明碱中的Michael加成受体单元部分还原(PL-1和PL-2),抗宫颈癌HeLa细胞增殖活性降低7~8倍;将Michael加成受体单元完全还原(PL-3),基本无活性;而肉桂酸上取代基的改变对活性影响较小.但是,采用碳碳键将荜茇明碱中的Michael加成受体单元与内酰胺连接的类似物PL-8,48 h抗宫颈癌HeLa细胞增殖的IC_(50)值为0.61μM,比荜茇明碱活性高近12倍.这些结果为阐明荜茇明碱抗宫颈癌作用的构效关系提供了一定的基础. Eight piperlongumine(PL)analogues were designed and synthesized,and their anti-cervical cancer HeLa cell proliferation activity in vitro were evaluated.It was found that the Michael acceptor units of PL was reduced,and its anti-cervical cancer HeLa cells proliferation activity was reduced by 7~8 times(PL-1 and PL-2).There was no Michael acceptor unit almost no activity(PL-3).The change of cinnamic acid substituent had little effect on the anti-cervical cancer HeLa cells activity.The IC_(50)of PL-8,an analogue linked to the Michael addition receptor unit and lactam in PL,was 0.61μM for 48 h against HeLa cells,nearly 12 times higher than that of PL.These results provide a basis for elucidating the structure-activity relationship of PL against cervical cancer.
作者 郑文宇 申昌德 邓修龙 王井妹 赵颖 路东亮 钱益平 ZHENG Wenyu;SHEN Changde;DENG Xiulong;WANG Jinmei;ZHAO Ying;LU Dongliang;QIAN Yiping(First Affiliated Hospital,Gannan Medical University;School of Chemical and Chemical Engineering,Gannan Normal University,Ganzhou 341000,China)
出处 《赣南师范大学学报》 2024年第3期79-84,共6页 Journal of Gannan Normal University
基金 赣州市指导性科技计划(GZ2021ZSF009) 赣南医科大学第一附属医院院级科技计划(YJYB202127) 国家自然科学基金(21762003,22365004)。
关键词 荜茇明碱 宫颈癌 活性 构效关系 Piperlongumine cervical cancer activity structure-activity relationship
  • 相关文献

参考文献4

二级参考文献36

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer [J]. Clin,2011, 61(2): 69-90.
  • 2Tewari KS, Sill MW, Long I-IJ 3rd,et al. Improved survival with bevacizumab in advanced cervical cancer [J]. N Engl Med, 2014,370 (8) : 734-743.
  • 3Mackay HJ, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND 184 [J]. Gynecol Oncol, 2010, 116(2): 163-167.
  • 4Monk BJ, Pandite LN. Survival data from a phase /I, open- label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer [J]. Clin Oncol , 2011, 29(36): 4845.
  • 5Symonds P, Gourley C, Davidson S,et al. LBA25_PR- CIRCCa: A randomised double blind phase II trial of carboplatin-paelitaxel plus cediranib versus carboplatin-- paclitaxel plus placebo in metastatic/recurrent cervical cancer [J]. Ann Oncol, 2014,25 (suppl 4). doi: 10.1093.
  • 6Conesa-Zamora P, Torres-Moreno D, Isaac MA, et al. Gene amplification and immunohistochemical expression of ERBB2 and EGFR in cervical carcinogenesis. Correlation with cell- cycle markers and HPV presence [J]. Exp Mol Pathol, 2013, 95(2): 151-155.
  • 7Goncalves A, Fabbro M, Lhomm6 C, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer [J]. Gynecol Oncol, 2008, 108(1) : 42-46.
  • 8Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open- label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer [J]. Clin Oncol, 2010, 28(22): 3562-3569.
  • 9Craig D. Woodworth, Laura P, et al. Inhibition of the Epidermal Growth Factor Receptor by Erlotinib Prevents Immortalization of Human Cervical Cells by Human Papillomavirus Type 16 [J]. Virology, 2011, 421(1) : 19-27.
  • 10Schilder R J, Sill MW, Lee YC, et al. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study [J]. Gynecol Cancer, 2009, 19(5): 929-933.

共引文献302

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部